EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database

Denis Mongin iD, Marco Matucci-Cerinic, Ulrich A Walker, Oliver Distler iD, Radim Becvar, Elise Siegert, Lidia P Ananyeva, Vanessa Smith, Juan Jose Alegre-Sancho iD, Sule Yavuz, Massimiliano Limonta, Gabriela Riemekasten und 7 weitere

Arthritis Care & Research · 2025

DOI: 10.1002/acr.25469 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis Care & Research, 2025. Verfasst von Denis Mongin und 18 weiteren Autor:innen. Beteiligte Einrichtung: Geneva University Hospitals, Geneva, Switzerland. Hauptthemen laut MEDLINE: Scleroderma, Diffuse, Glucocorticoids, Skin, Immunosuppressive Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Geneva University Hospitals, Hôpitaux Universitaires de Genève.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study is to evaluate whether adding oral glucocorticoids to immunosuppressive therapy improves skin scores and ensures safety in patients with early diffuse cutaneous systemic sclerosis (dcSSc).

Methods

We performed an emulated randomized trial comparing the changes from baseline to 12 ± 3 months of the modified Rodnan skin score (mRSS: primary outcome) in patients with early dcSSc receiving either oral glucocorticoids (≤20 mg/day prednisone equivalent) combined with immunosuppression (treated) or immunosuppression alone (controls), using data from the European Scleroderma Trials and Research Group. Secondary end points were the difference occurrence of progressive skin or lung fibrosis and scleroderma renal crisis. Matching propensity score was used to adjust for baseline imbalance between groups.

Results

We matched 208 patients (mean age 49 years; 33% male; 59% anti‐Scl70), 104 in each treatment group, obtaining comparable characteristics at baseline. In the treated group, patients received a median prednisone dose of 5 mg/day. Mean mRSS change at 12 ± 3 months was similar in the two groups (decrease of 2.7 [95% confidence interval {95% CI} 1.4–4.0] in treated vs 3.1 [95% CI 1.9–4.4] in control, P = 0.64). Similar results were observed in patients with shorter disease duration (≤ 24 months) or with mRSS ≤22. There was no between‐group difference for all prespecified secondary outcomes. A case of scleroderma renal crisis occurred in both groups.

Conclusion

We did not find any significant benefit of adding low‐dose oral glucocorticoids to immunosuppression for skin fibrosis, and at this dosage, glucocorticoid did not increase the risk of scleroderma renal crisis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, DiffuseGlucocorticoidsSkinImmunosuppressive AgentsPrednisoneHumansMaleMiddle AgedFemaleAdministration, OralFibrosisAdultDatabases, FactualTreatment OutcomeEuropeDrug Therapy, Combination

Substanzen

GlucocorticoidsImmunosuppressive AgentsPrednisone

Autor:innen und Institutionen

  • Geneva University Hospitals, Geneva, Switzerland.
  • IRCCS San Raffaele Scientific Institute, IRCCS San Raffaele Hospital, and Vita-Salute San Raffaele University, Milan, Italy.
  • University Hospital Basel, Basel, Switzerland.
  • University Hospital Zurich, Zurich, Switzerland.
  • University, Prague, Czech Republic.
  • Charité University Hospital, Berlin, Germany.

ORCID-Profile: Denis Mongin, Oliver Distler, Juan Jose Alegre-Sancho, Elena Rezus, Madelon Vonk, Francesco Del Galdo, Michele Iudici

Förderung

  • Geneva University Hospitals
  • Hôpitaux Universitaires de Genève

Zitieren

APA

Mongin, D., Matucci-Cerinic, M., Walker, U. A., Distler, O., Becvar, R., Siegert, E., Ananyeva, L. P., Smith, V., Alegre-Sancho, J. J., Yavuz, S., Limonta, M., Riemekasten, G., Rezus, E., Vonk, M., Truchetet, M. E., Del Galdo, F., Courvoisier, D. S., Iudici, M., & EUSTAR Collaborators (2025). Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database. Arthritis Care & Research. https://doi.org/10.1002/acr.25469

Vancouver

Mongin D, Matucci-Cerinic M, Walker UA, Distler O, Becvar R, Siegert E, et al. Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database. Arthritis Care & Research. 2025. doi:10.1002/acr.25469

BibTeX
@article{Mongin2025,
  author = {Mongin, Denis and Matucci-Cerinic, Marco and Walker, Ulrich A and Distler, Oliver and Becvar, Radim and Siegert, Elise and Ananyeva, Lidia P and Smith, Vanessa and Alegre-Sancho, Juan Jose and Yavuz, Sule and Limonta, Massimiliano and Riemekasten, Gabriela and Rezus, Elena and Vonk, Madelon and Truchetet, Marie-Elise and Del Galdo, Francesco and Courvoisier, Delphine S and Iudici, Michele and EUSTAR Collaborators, EUSTAR Collaborators},
  title = {Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database},
  journal = {Arthritis Care & Research},
  year = {2025},
  doi = {10.1002/acr.25469}
}
Kostenlos starten →